【产品介绍】：

生物活性：Entecavir-13C2,15N (BMS200475-13C2,15N; SQ34676-13C2,15N) is a 13C- and 15N-labeled Entecavir (HY-13623). Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Entecavir-13C2,15N 相关抗体:
HBcAg Antibody (YA910)
HBsAg Antibody (YA913)
分子量：280.26
Formula：C1013C2H15N415NO3
非标记 CAS：142217-69-4
中文名称：恩替卡韦-13C2,15N
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (536 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.
 [Content Brief]
[2]. Innaimo SF, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997 Jul;41(7):1444-9.
 [Content Brief]
[3]. Rivkin A, et al. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin. 2005 Nov;21(11):1845-57.
 [Content Brief]
[4]. Genovesi EV, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother. 1998 Dec;42(12):3209-18.
 [Content Brief]